ArticleFrontiers in oncology2025
Diagnostic value of multi-gene methylation in colorectal cancer screening.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Association of immune-related gene DNA methylation patterns with tumor progression in colorectal cancer: a clinical translational study.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic value and clinical application of multi-gene methylation assay in colorectal cancer (CRC) screening. Methods: This was a single-center, retrospective, real-world study conducted at the First Affiliated Hospital of Shantou University Medical College, China. A total of 450 participants were enrolled from January 2023 to December 2024, including 150 healthy individuals, 120 colorectal polyp patients, and 180 CRC patients. The methylation status of six plasma-derived loci (SEPT9-R1, SEPT9-R2, BCAT1, IKZF1, BCAN, and VAV3) was assessed using real-time multiplex quantitative PCR (qPCR). The diagnostic performance and predictive factors of the multi-gene methylation assay for CRC detection were assessed. Results: The multi-gene methylation assay effectively differentiated healthy controls, colorectal polyp patients, and CRC patients (P < 0.001), and methylation levels increased with advancing tumor stage. The combined panel demonstrated superior diagnostic accuracy over single-gene assays, yielding an AUC of 0.958 (95% CI: 0.934-0.982) in the training cohort and 0.952 (95% CI: 0.920-0.984) in the validation cohort. Multivariate analysis further identified tumor size (OR = 1.974, 95% CI: 1.321-2.950, P = 0.005) and TNM stage (OR = 2.117, 95% CI: 1.452-3.087, P = 0.002) as independent predictors of multi-gene methylation positivity. Conclusion: Multi-gene methylation detection showed high diagnostic value for CRC and may serve as a valuable adjunct tool in CRC screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.